Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04562129 · ClinicalTrials.gov registry record · Phase 2
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
A Phase 2 study of Melanoma Stage IV and Melanoma Stage III, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT04562129: Recruiting Phase 2 study of Melanoma Stage IV and Melanoma Stage III, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT04562129 is a Phase 2 study of Melanoma Stage IV and Melanoma Stage III that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 29 participants, below the 101-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04562129, a Phase 2 study of Melanoma Stage IV and Melanoma Stage III, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
Primary Outcome
Response rate (Complete Response + Partial Response) of HD IL2 plus low dose ipilimumab followed sequentially by nivolumab in patients with inoperable stage III or stage IV melanoma who have either failed prior treatment with anti-PD1 immunotherapy (nivolumab or pembrolizumab) or have demonstrated tumor progression following such therapy.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Interleukin-2
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-09-24 |
| Est. Completion | 2029-11 |
| Phase | Phase 2 |
What NCT04562129 shows while recruiting
NCT04562129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 101-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (71% lower).
The record links to 3 conditions, with Melanoma Stage IV appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04562129 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04562129 about?
NCT04562129 is a clinical study titled "IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients". The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
What is the current status of trial NCT04562129?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2020-09-24. Estimated completion is 2029-11.
What conditions does trial NCT04562129 study?
This clinical trial studies the following conditions: Melanoma Stage IV, Melanoma Stage III, Inoperable Disease.
What interventions are being tested in trial NCT04562129?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT04562129?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04562129 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04562129's enrollment target sits among peer trials
29 15th of 17 higher than 3 of 17 other Melanoma Stage IV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma Stage IV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
RECRUITING · Phase 2
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
RECRUITING · Phase 2
-
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI